Henk J.C. Meijerink, Director & Co-founder
Henk Meijerink (MSc Biochemistry) is a biochemist with over 25 years of experience in life sciences from start-ups to market introductions. He is originator of several patents and innovative technologies. He has set up companies in clinical diagnostics, disinfectants and preservatives for research in anatomy and pathology. Among others, he did research on novel fixatives for organic tissue to improve clinical diagnosis. He has developed drugs and medical devices for wound healing in chronic (diabetic and non-diabetic) ulcers and indications like periodontitis, gingivitis, psoriasis, dermatitis and onychomycosis, and performed preclinical research and clinical trials. In 2006, together with Mr. Lekhram Changoer and Mr. Jos Fleskens, he started CFM Pharma BV (www.cfmpharma.com), a pharmaceutical company with organic vanadium based single dose intravenous treatments for secondary tissue injury. A myocardial infarction treatment is in phase II and kidney failure, trauma, stroke and burn wounds trials are being scheduled.
Lekhram Changoer, Director & Co-founder
Lekhram Changoer (MSc Organic Chemistry, BSc Analytical/Organic Chemistry) has co-founded several intellectual property based pharmaceutical companies’ different stages from clinical development to global sales of registered products. Already during the early stages in his career, he built his knowledge and experience in initiating clinical trials and R&D processes, product development, defining business plans, fundraising and building his network of relations within the pharmaceutical industry, CRO’s, GMP facilities and universities. His career spans 20 years of international experience in sales & marketing, product development, R&D and QA for technical, consumer healthcare and pharmaceutical products. He was co-founder of CanChew Biotechnologies (where he initiated multiple patents on chewing gum compositions comprising cannabinoids). In addition to being co-founder and CEO of CFM Pharma, he is co-founder, president and COO of APET Holding, co-founder and CTO of Axim Biotechnologies (USA and the Netherlands), co-founder of APIRx Pharmaceuticals and board member and partner of Sanammad Foundation (the Netherlands).
Magdy M. Abdel-Malik
Dr. Magdy Abdel-Malik is a global executive innovation leader with unique blend of R&D and business development experience within the consumer healthcare and pharmaceutical industries. He is a proven leader with Ph.D. in Organic Chemistry and over 20 years of experience with world-class Corporations such as Pfizer, Warner-Lambert and others. Magdy has a deep understanding of identifying, evaluating, partnering, development, and bringing new products to consumer healthcare (OTC), pharmaceutical, medical device markets cosmetics and nutritional industries. Dr. Abdel-Malik founded (2007) Quaestio GP (www.quaestiogp.com), a boutique consulting firm specializing in external innovation and strategic partnerships that expand product portfolios and enable new business creation within the Healthcare and Life Sciences industries. Prior to that Dr. Abdel-Malik hold the Director, Global External Opportunities, Pfizer Consumer Healthcare and he was responsible for identifying and aquiring external technologies and products to achieve above-market growth for the $4B Consumer Healthcare business. Created and implemented the company’s Technology Search Process, the first known organized external search initiative in the consumer healthcare industry. Dr. Abdel-Malik also held Director, Scientific Affairs, Global Complementary Medicines position at Warner-Lambert (acquired by Pfizer on 2000).